Cerebral vascular mean transit time in healthy humans: a comparative study with PET and dynamic susceptibility

Masanobu Ibaraki1, Hiroshi Ito, Eku Shimosegawa

  • 1Department of Radiology and Nuclear Medicine, Akita Research Institute of Brain and Blood Vessels, Akita, Japan. iba@akita-noken.go.jp

Insights

Positron emission tomography (PET) and dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) provide different quantitative measurements of cerebral mean transit time (MTT). Quantitative MTT measured by DSC-MRI was significantly shorter than PET, impacting cerebrovascular disease interpretation.

Area of Science:

  • Neuroimaging
  • Cerebrovascular physiology
  • Medical physics

Background:

  • Cerebral mean transit time (MTT) is a key indicator of cerebral circulation.
  • Positron emission tomography (PET) and dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) are clinical tools for quantitative MTT determination.

Purpose of the Study:

  • To establish normal values for MTT using both PET and DSC-MRI.
  • To identify and analyze discrepancies in MTT measurements between PET and DSC-MRI.

Main Methods:

  • Seven healthy volunteers underwent (15)O-PET (H(2)(15)O and C(15)O) and 1.5 T gradient-echo echo-planar DSC-MRI.
  • Deconvolution analysis was applied to DSC-MRI data following contrast agent bolus injection.

Main Results:

  • Relative measurements of cerebral blood volume (CBV), cerebral blood flow (CBF), and MTT showed good agreement between PET and DSC-MRI.
  • Quantitative MTT was significantly shorter with DSC-MRI (2.8–3.5 secs) compared to PET (3.9–4.8 secs) in cortical regions and centrum semiovale.

Conclusions:

  • Discrepancies in quantitative MTT arise from differences in vascular component sensitivity between PET and DSC-MRI.
  • PET CBV measurement is sensitive to all vascular components, while DSC-MRI originates from microvasculature near brain parenchyma.
  • These differences may affect the interpretation of MTT in cerebrovascular disease patients.